Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · February 09, 2022

First-Line TKI With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC

Journal of the National Cancer Institute

 

Additional Info

Journal of the National Cancer Institute
Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated NSCLC
J. Natl. Cancer Inst 2022 Jan 30;[EPub Ahead of Print], XS Wang, YF Bai, V Verma, RL Yu, W Tian, R Ao, Y Deng, JL Xia, XQ Zhu, H Liu, HX Pan, L Yang, YK He, HS Bai, X Luo, Y Guo, MX Zhou, YM Sun, ZC Zhang, SM Li, X Cheng, BX Tan, LF Han, YY Liu, K Zhang, FX Zeng, L Jia, XB Hao, YY Wang, G Feng, K Xie, Y Lu, M Zeng

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading